Kenya is set to make history in the fight against HIV by rolling out the injectable HIV vaccine, Lenacapavir, starting in January 2026. As one of the first nine countries globally to introduce this twice-yearly preventive injection, Kenya is positioning itself as a leader in HIV prevention. This initiative will ensure that the vaccine is available for free at public hospitals, especially targeting vulnerable groups in urban and rural areas.
The injectable HIV vaccine, Lenacapavir, is a long-acting pre-exposure prophylaxis (PrEP) that provides a convenient and effective alternative to daily oral pills. The rollout of the vaccine is part of Kenya’s broader efforts to expand access to HIV prevention tools and reduce new infections, particularly among young people and high-risk populations.
Initial Rollout Facilities for Injectable HIV Vaccine
The National AIDS and STI Control Programme (NASCOP) has worked closely with international partners to ensure a smooth and equitable distribution of the injectable HIV vaccine. The initial rollout will begin in major public hospitals with the infrastructure and capacity to handle large-scale HIV prevention programs.
Major Public Hospitals Leading the Initiative
The following public hospitals have been selected to lead the rollout of the injectable HIV vaccine due to their experience in HIV care and their capacity to manage preventive programs:
- Kenyatta National Hospital, Nairobi
- Moi Teaching and Referral Hospital, Eldoret
- Jaramogi Oginga Odinga Teaching and Referral Hospital, Kisumu
These hospitals will play a key role in administering the vaccine and ensuring its widespread availability.
County-Level and Regional Hospitals Receiving the Drug
In addition to major public hospitals, the injectable HIV vaccine will also be distributed to county-level and regional hospitals across Kenya to ensure that rural and underserved populations have access to the vaccine. These facilities include:
- Coast General Teaching and Referral Hospital
- Embu Level 5 Hospital
- Kisii Teaching and Referral Hospital
- Kakamega County General Hospital
- Nakuru Level 5 Hospital
- Garissa County Referral Hospital
- Meru Teaching and Referral Hospital
- Machakos Level 5 Hospital
- Kisumu County Referral Hospital
- Bungoma County Referral Hospital
These hospitals are critical in ensuring that the HIV vaccine reaches communities across the country, particularly those outside major urban centers.
Cost and Access in Public and Private Hospitals
The injectable HIV vaccine will be offered free of charge at public hospitals across Kenya. This move is part of the government’s commitment to providing equitable access to innovative healthcare solutions for all Kenyans.
In contrast, private hospitals may introduce fees for the vaccine, though ongoing discussions aim to ensure that costs remain reasonable while maintaining supply and sustainability. The goal is to balance accessibility and sustainability to ensure that all eligible individuals can access the vaccine.
How the Injectable HIV Vaccine Works
Lenacapavir is administered as an injection under the skin of the abdomen. It is a long-acting form of pre-exposure prophylaxis (PrEP) that provides protection against HIV for up to six months. The initiation process involves starting with oral Lenacapavir tablets to prepare the body for the injection. After two weeks, the first injection is given, followed by a second injection after six months.
The convenience of biannual dosing is expected to improve adherence rates and reduce the challenges associated with daily oral PrEP, such as stigma and forgetfulness. Lenacapavir offers a discreet, highly effective HIV prevention method, especially for individuals at high risk.
The Importance of Lenacapavir for HIV Prevention
The rollout of Lenacapavir is a game-changer in Kenya’s HIV prevention strategy. The long-acting injectable offers a sustainable, effective way to prevent HIV infection, particularly for populations that struggle with daily medication adherence. Health officials are optimistic that Lenacapavir will make HIV prevention more accessible and effective, contributing to the country’s Vision 2030 goals.
Lenacapavir’s introduction marks a significant milestone in Kenya’s fight against HIV. With its FDA approval in June 2025, the vaccine is now part of an international initiative to combat HIV across countries like South Africa, Uganda, Zambia, and Zimbabwe. Kenya’s participation in this global rollout demonstrates its commitment to advancing HIV prevention efforts.
